Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer.
David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Articles by David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?
2
Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma
3
26 A Nomogram for Predicting High Axillary Disease Burden in Patients With Localized HR+, HER2-Negative Breast Cancer Following Neoadjuvant Chemotherapy
4
27 Transfusion and Anemia Management Strategies in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Literature Review
5